Since transitioning from a successful public accounting career, Michael Celano has spent the last 16 years as a COO/CFO and board member with a series of high-growth life science companies. Mr. Celano is currently is the chairman of the board of directors of OraSure Technologies (NASDAQ: OSUR), a molecular tools and diagnostic company. He also was on the board of Performance Health, a private equity-funded consumer healthcare products company sold to Patterson Medical. Mr. Celano was most recently the chief operating officer and previously the CFO of Recro Pharma (NASDAQ: REPH), a specialty pharmaceutical company.
Mr. Celano has served as CFO of Kensey Nash, a publicly held biomaterials company, until its acquisition by DSM. Previously, Mr. Celano served as CFO for BioRexis Pharmaceutical, a biopharmaceutical company, which was sold to Pfizer. Before joining BioRexis, Mr. Celano spent 24 years in public accounting. Starting with Arthur Andersen in 1980, Mr. Celano spent his early career servicing venture-funded, public technology-based companies. He focused on the life science industry as it grew in the late 1980s, and eventually co-chaired Andersen’s U.S. Life Sciences Practice. After leaving Andersen, Mr. Celano held similar leadership positions with KPMG. During his public accounting career, he served more than 40 life science clients, including serving as lead audit partner for 17 public life science companies.